Drug Profile
Crizanlizumab - Novartis
Alternative Names: Adakveo; Crizanlizumab-tmca - Novartis; SEG-101; Sel G1Latest Information Update: 31 Jan 2024
Price :
$50
*
At a glance
- Originator Selexys Pharmaceuticals
- Developer Novartis
- Class Antivirals; Monoclonal antibodies; Vascular disorder therapies
- Mechanism of Action P selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Vaso-occlusive crisis
- Phase II Priapism; Vascular disorders
- Phase I/II Myelofibrosis
Most Recent Events
- 09 Dec 2023 Efficacy and adverse events data from a phase-II SPARTAN clinical trials in Priapism presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Pharmacokinetics, efficacy and adverse events data from phase II trial in Vaso-occlusive crisis presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem 2023)
- 09 Dec 2023 Pooled analysis of adverse events data from a phase II studies SUSTAIN trial, SOLACE-adults trial, the pediatric SOLACE-Kids trial, phase III STAND trial in sickle cell anaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)